# A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF

> **NCT02411786** · PHASE1 · COMPLETED · sponsor: **University of Wisconsin, Madison** · enrollment: 40 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** pTVG-AR
- **BIOLOGICAL:** gm-csf

## Key facts

- **NCT ID:** NCT02411786
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-24
- **Primary completion:** 2019-05-01
- **Final completion:** 2020-11-28
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02411786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02411786, "A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02411786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*